SNCA-009-C3

General

Cell Line

hPSCreg name DANi009-C
Cite as:
DANi009-C (RRID:CVCL_XJ31)
Alternative name(s)
SNCA-009-C3
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-4
(AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-B-1
(AST18-7A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-2
(AST18-7B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-3
(AST18-5D)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-4
(AST18-6A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-A-5
(AST23-2KO-II8B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-A
(AST22, AST23, SAMEA3319992)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-B
(AST18)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-A
(SFC828-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-B
(SFC828-03-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-A
(SFC831-03-01)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-B
(SFC831-03-03)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-C
(SFC831-03-05)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-C
(SFC828-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-A
(SFC829-03-02)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-B
(SFC829-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-C
(SFC829-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi008-B
(G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi083-A
(SFC830-04-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
DANi008-F
(SNCA-008-C6)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson Disease
STBCi083-B
(SFC830-04-08)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
MPIi003-A-1
(IM2GC, L2-2GC)
Donor diseases:
obsolete_Parkinson's disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
LCSBi009-A-1
(RHOT1_R272Q_clone18_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-1
(RHOT1_R450C_clone6_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-2
(RHOT1_R450C_clone10_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi012-A-1
(RHOT1_T610A_clone62.19.37_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi008-A-1
(delP GC13, DJ-1-delP GC13)
Donor diseases:
Parkinson Disease
SUSMi005-A-1
(SNCA3X 0KO C1, SNCA3X 0KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-2
(SNCA3X 1KO C2, SNCA3X 1KO C1)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-3
(SNCA3X 2KO C1, SNCA3X 2KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-4
(SNCA3X 3KO C1, SNCA3X 3KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-5
(SNCA3X 4KO C1, SNCA3X 4KO C2)
Donor diseases:
obsolete_Parkinson's disease
ICGi015-B-1
(m6.7pCyto-17)
Donor diseases:
Parkinson Disease
ICGi015-B-2
(m6.7pCyto-21)
Donor diseases:
Parkinson Disease
ICGi015-B-3
(m6.7pCyto-24)
Donor diseases:
Parkinson Disease
ICGi034-A-1
(PD30-XBP-RFP-6, PD30-4-7-XBP-RFP-6)
Donor diseases:
obsolete_Parkinson's disease
ICGi034-A-2
(PD30-4-7-XBP-RFP-51, PD30-XBP-RFP-51)
Donor diseases:
obsolete_Parkinson's disease
LCSBi011-A-1
(RHOT1_T351A_clone25.2_IsogenicControl)
Donor diseases:
Parkinson Disease
LCPHi001-A
Donor's gene variants:
GBA
Donor diseases:
obsolete_Parkinson's disease
UNAMi002-A
(IFC-UNAM iPD02-S)
Donor diseases:
Parkinson Disease
UNAMi003-A
(IFC-UNAM iPD03-PINK1)
Donor diseases:
Parkinson Disease
STBCi004-B
(SFC832-03-06)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi004-C
(SFC832-03-07)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
PNUSCRi004-A
(GBA PD iPSC8)
Donor diseases:
Parkinson Disease
Last update 17th October 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Danish Research Institute of Translational Neuroscience (DAN)
Owner Danish Research Institute of Translational Neuroscience (DAN)
Distributors
Derivation country Denmark

External Databases

BioSamples SAMEA5912487
Cellosaurus CVCL_XJ31
Wikidata Q93503258

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Genetic variants
SNCA (target)
Heterozygous
SNCA duplication
DANi-009C Molecular analysis-v9c.tif
QPCR amplification of SNCA genomic DNA
Is clinical information available? age of onset 41

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA5912488

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information http://biobanknetwork.telethon.it/
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of the Institute Giannina Gaslini
Approval number 3343DSc/fg
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Often referred to as a blast cell. Unlike other usages of the suffix -blast a lymphoblast is a further differentiation of a lymphocyte, T- or B-, occasioned by an antigenic stimulus. The lymphoblast usually develops by enlargement of a lymphocyte, active re-entry to the S phase of the cell cycle, mitogenesis and production of much m-RNA and ribosomes.
Source cell line vendor Telethon Biobank

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium TeSR™ E8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-81
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 21
Karyotyping method: G-Banding

Other Genotyping (Cell Line)